We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

Since rolling out its pulsed field ablation system for treating atrial fibrillation earlier this year, Boston Scientific has ...

Boston Scientific BSX is gaining traction in the international markets. New regulatory approvals and accretive acquisitions ...

In a report released today, Michael Matson from Needham maintained a Hold rating on Boston Scientific (BSX – Research Report). The ...

Canaccord Genuity analyst William Plovanic has maintained their bullish stance on BSX stock, giving a Buy rating today. William Plovanic has ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Boston Scientific Corp. (BSX) on Wednesday reported third-quarter earnings of $469 million. On a per-share basis, the Marlborough, Massachusetts-based company said it had net income of 32 cents.

Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S. The ACURATE neo2 Aortic ...

WASHINGTON, D.C.—Boston Scientific’s long-awaited transcatheter aortic heart valve missed its mark in a head-to-head study aimed at bringing the implant to the U.S.—but the company believes ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...